Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
04 December, 2021 13:28 IST
RBI approves re-appointment of Uday Kotak as MD of Kotak Mahindra Bank
Source: IRIS | 16 Dec, 2020, 03.01PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

 Kotak Mahindra Bank (KMB), one of the leading private sector lenders, on December 14 said the RBI has approved the re-appointment of Uday Kotak as managing director of the bank for a further period of three years. The private sector lender also approved the appointment of part-time chairman Prakash Apte for three years.

"The Reserve Bank of India (RBI) has vide its letter dated Dec. 14, 2020, granted approval for the re-appointments of Prakash Apte as Part-time Chairman; Uday Kotak as MD & CEO; and Dipak Gupta as Joint MD for a period of 3 years, with effect from Jan. 1, 2021," the bank said on Monday.

It may be noted that the board of the bank and the shareholders had approved these re-appointments, subject to the approval of the RBI, at their respective meetings held on May 13, 2020, and Aug. 18, 2020, the bank said.

 

Shares of Kotak Mahindra Bank  are trading at Rs 1,944.55, down Rs 5.9, or 0.30%  at the Bombay Stock Exchange (BSE) on Wednesday at 1:39 p.m.

The scrip has touched an intra-day high of Rs 1,964.10 and low of Rs 1,937. The total volume of shares traded at the BSE is 193,761.In the earlier session, the shares rose 0.53%, or Rs 10.3, at Rs 1,950.45.

Currently, the stock is trading down 0.69% from its 52-week high of Rs 1,964.10  and above 94.39% over the 52-week low of Rs 1,000.35.



 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
L&T inks pact with Kemroc to distribute cutting-edge products in India - 03-Dec-2021 17:07
Delta Corp's associate to invest in WSPL Containers - 03-Dec-2021 16:51
Morepen gets USFDA nod for Fexofinadine (Allegra) - 03-Dec-2021 16:25
Motilal Oswal recommends Buy on TCI; target price of Rs 790 - 02-Dec-2021 13:08
Max Financial Services: Growth to pick up over FY21-26; margin trajectory stable - 02-Dec-2021 12:04
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer